Researchers have found that the characteristics of tumors are determined by their genetic makeup. Therefore, cancer treatment can begin at the genetic level by targeting specific genes to influence tumor behavior and achieve therapeutic outcomes. Tumor driver genes are associated with cancer progression and can help assess prognosis, as well as the risks of recurrence and metastasis. Drug-related genes provide valuable guidance for therapy selection by indicating drug sensitivity or resistance. Understanding the genetic profile of a tumor forms the basis for treatment planning. By identifying the appropriate genes, more precise and effective cancer therapies can be delivered, maximizing clinical benefit.

Genecast Comprehensive is a hybrid capture based test that uses targeted NGS to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels), and also reports a tumor mutational burden (TMB) score and microsatellite stability (MS) status in 769 genes using DNA extracted from FFPE tumor tissue samples from solid tumor patients. The test can also be used to detect fusions in 52 genes from RNA. Almost covering all solid cancer drivern genes and chemotherapeutic drug treatment related genes in NCCN guidelines. In addition, the test is intended to provide tumor profiling information to qualified healthcare professionals for solid tumor patients.

Applicable Cancer Types

Specifications